Introduction {#s1}
============

Metabolic syndrome (MetS) is a constellation of cardiometabolic risk factors, the core components of which involve insulin resistance, abdominal obesity, hypertension, hyperglycemia, and dyslipidemia. In the general population, MetS increases the risks of cardiovascular disease (CVD), type 2 diabetes mellitus (T2DM) and all-cause mortality ([@B1]). Reassuringly, modification of MetS severity is associated with a concomitant reduction in the risk of further T2DM and CVD ([@B2]). So, identifying patients with MetS is critical for precise intervention targeting insulin resistance and CVD protection. It is well-known that MetS is prevalent in type 2 diabetes, but the exact status of MetS in different types of diabetes and its determinants remain undefined.

Autoimmune diabetes results from immune-mediated destruction of pancreatic insulin-producing β cells and subsequent insulin deficiency. The two subtypes of autoimmune diabetes, classic type 1 diabetes mellitus (T1DM) and latent autoimmune diabetes in adults (LADA), are of great clinical heterogeneity and thus different treatment regimes. While T1DM is characterized by its acute onset and life-long dependence on exogenous insulin, LADA is a slowly progressive form of T1DM, characterized by adult onset, presence of circulating islet autoantibodies, and insulin independence at least within 6 months after diagnosis of diabetes ([@B3]). Though not requiring insulin therapy initially, patients with LADA exhibit pronounced impairment in the maximally stimulated β-cell secretory capacity compared with T2DM patients ([@B4]), and β-cell secretory capacity in LADA deteriorates over time at a 3-fold higher rate than in T2DM ([@B5]). Generally, LADA lies in between T1DM and T2DM regarding autoimmune, inflammatory, metabolic and genetic features, often described as "end of the rainbow" ([@B6]). T1DM, LADA and T2DM jointly constitute a continuum of varying degrees of clinical features and β-cell function.

The presence of MetS in diabetes is a strong indicator for increased insulin resistance, which is common in T2DM ([@B7]). Growing evidence suggests that insulin resistance predisposes to accelerated β cell loss, being involved in the pathogenesis of autoimmune diabetes ([@B8]). A study reported that in European patients with diabetes, the prevalence of MetS was quite high, 31.9% in T1DM, 41.9% in LADA and 88.8% in T2DM ([@B9]). Although there is still a lack of randomized controlled trials that addresses the benefits of lowering Mets rates in autoimmune diabetes, several randomized controlled trials and epidemiological studies showed the benefits of vigorous control of glycemia, lipids and blood pressure on mortality and coronary artery disease in T1DM patients ([@B10], [@B11]). In this connection, a heterogeneity of MetS susceptibility genes was observed across ethnicities ([@B12]). Moreover, Asian populations have a different distribution of glutamic acid decarboxylase autoantibody (GADA) titers and a lower adiposity than Caucasians ([@B13], [@B14]), and therefore, the prevalence and features of MetS in Asians may differ from those in Caucasians. Nevertheless, there is still a lack of large-scale multicenter studies to document the prevalence of MetS in the entire spectrum of diabetes in Asian populations, and whether risk factors for MetS in the general population, including age, smoking, alcohol consumption, residence and family history of diabetes, also applied to population with autoimmune diabetes remained unclear ([@B15], [@B16]).

We analyzed the data from a nationwide, multicenter, cross-sectional survey to investigate the prevalence of MetS and its determinants in Chinese patients with newly diagnosed diabetes.

Methods {#s2}
=======

Research Design and Participants
--------------------------------

The present study was a nationwide, multi-center, cross-sectional survey conducted from April 2015 to October 2017. Patients were recruited consecutively from 46 tertiary care hospitals in 20 provincial administration areas and 4 municipalities, across the seven geographic regions of China (4 Northeast, 8 North, 3 Northwest, 9 Central, 3 Southwest, 7 South, and 12 East), thereby, representing the diversity in climates, cultures, and ethnicities of the Chinese populations. This survey was designed to collect detailed data on outpatients with newly-diagnosed diabetes, i.e., within 1 year of diabetes. The ethics review committee/institutional review board of each participating hospital approved the study, and the World Medical Association\'s Declaration of Helsinki was followed. Informed consent was obtained from all the participants before data collection. The inclusion criteria were as follows: (1) diagnosis of diabetes using the World Health Organization (WHO) 1999 criteria ([@B17]) and at ≥30 years of age; (2) diabetes duration \< 1 year; and (3) outpatients attending metabolism and endocrinology clinics. The exclusion criteria were as follows: (1) pregnancy at diagnosis or gestational diabetes mellitus (GDM); (2) secondary or special type of diabetes; (3) presence of acute diseases that could interfere with the glucose metabolism; and (4) any malignancy. After excluding 1,804 patients whose data on key variables for diagnosis of MetS were missing, the remaining 15,492 patients were included for analysis ([Figure 1](#F1){ref-type="fig"}).

![Flow diagram and classification of 15,492 newly-diagnosed adult-onset patients with diabetes for MetS status in China. GDM, gestational diabetes mellitus; GADA, glutamic acid decarboxylase autoantibody; MetS, metabolic syndrome; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; LADA, latent autoimmune diabetes in adults.](fendo-10-00661-g0001){#F1}

Classification of Diabetes
--------------------------

Diagnosis of T1DM was based on acute onset of insulin-requiring diabetes, proneness to ketosis or ketoacidosis, impaired insulin secretion or GADA positivity. LADA was diagnosed based on the Immunology of Diabetes Society (IDS) criteria ([@B3]): (1) GADA positivity; (2) diagnosed at ≥30 years of age; (3) insulin independence for at least 6 months postdiagnosis. GADA-negative patients not requiring immediate insulin therapy were diagnosed as with T2DM.

Definition of Metabolic Syndrome
--------------------------------

MetS was defined using the 2017 Chinese Diabetes Society\'s (CDS) criteria ([@B18]), and was diagnosed when three or more of the following criteria were met: (1) abdominal obesity: waist circumference ≥90 cm in men and ≥85 cm in women; (2) hyperglycemia: fasting blood glucose ≥6.1 mmol/L or 2-h blood glucose ≥7.8 mmol/L or previously diagnosed diabetes with treatment; (3) hypertension: blood pressure ≥130/85 mmHg or currently under antihypertension therapy; (4) fasting triglycerides (TGs) ≥1.70 mmol/L; (5) fasting high-density lipoprotein cholesterol (HDL-C) \<1.04 mmol/L. All patients in this study were defined to fulfill the criteria for hyperglycemia. Lipid-lowering therapies were not included in the criteria.

Estimation of Beta Cell Function and Insulin Resistance
-------------------------------------------------------

An updated Homeostasis Model Assessment (HOMA2) calculator (University of Oxford, Oxford, UK) ([@B19]) was employed for estimation of beta cell function (HOMA2-B) and insulin resistance (HOMA2-IR), based on fasting plasma glucose and C-peptide concentrations.

Data Collection Procedures
--------------------------

Demographic characteristics, medical history and lifestyle information were collected using a standard questionnaire via face-to-face interviews by uniformly-trained research nurses. Body height, weight, waist circumference, and blood pressure were measured by the research nurses. Medication information was retrieved from medical records. Smoking/drinking was classified as a binary variable assessed using a yes or no question depending on the current smoking/drinking status. Educational attainment was classified into three categories: "junior high school or lower," "senior high school," or "tertiary or above". The Qinling Mountains and Huaihe River marked the boundary between North and South of China.

Laboratory Assays
-----------------

Fasting plasma glucose (FPG), TGs, HDL-C, LDL cholesterol (LDL-C), fasting C-peptide (FCP), and hemoglobin A1c (HbA1c) were assayed at the study sites by standard methods using overnight fasting venous blood samples. Postprandial blood samples were tested for 2-h postprandial plasma glucose (PPG) and C-peptide (PCP). Serum samples were transported to the core laboratory (Central South University) for antibody assays on ice within the day and stored at −80°C before analysis.

FCP and PCP were measured uniformly by the chemiluminescence method, but different kits were used in the participating centers. In Central South University, FCP and PCP were measured using Adiva Centaur Systema kit (Siemens, Munich, Germany).

GADA was measured by radioligand binding assays in duplicate, using *in vitro* transcribed and translated \[^35^S\] methionine-labeled recombinant human GAD65 (aa: 1--585) as previously described ([@B13], [@B20]). Briefly, 5 μL of human serum was incubated overnight at 4°C with 30,000 cpm of the ^35^S-GAD in a final volume of 200 μL in TBST buffer (50 mM Tris-HCl, 150 mM NaCl, 0.15% v/v Tween-20, pH 7.2). Subsequently, the immune complexes were isolated, washed, mixed with scintillation fluid (PerkinElmer, CT, USA) and radioactivity determined (Micro Beta Trilux 1450 counter; PerkinElmer, Finland). The cut-off value of ≥18 U/ml of WHO units, i.e., the 99th percentile of 405 healthy subjects, was used to define positivity for GADA. Further validations were performed to confirm the positivity. The sensitivity and specificity of the GADA assay were 82% and 97.8%, respectively, as assessed in the 2016 islet autoantibody standardization program (IASP 2016).

Statistical Analysis
--------------------

SPSS 20.0 software (IBM Corporation, Armonk, NY, USA) was used to perform all the data analysis unless specified. Normal distribution was checked using Kolmogorov-Smirnov test. Continuous data were presented as mean ± standard deviation (SD) if their normality was not rejected, or median (interquartile range) otherwise. Categorical variables were expressed as number (percentage). For variables with normal distribution, comparisons between groups were performed using independent Student *t*-test. Mann-Whitney *U* test was used to compare differences of variables whose normality was rejected. χ^2^ test or Fisher\'s exact test where appropriate was used to compare differences in categorical variables between groups. Effect sizes of comparisons between groups were calculated as previously reported ([@B21], [@B22]). After checking P-P plots of standardized regression residuals for normality, logistic regression analysis was performed to obtain odds ratios (ORs) and their 95% confidence intervals (CIs) of types of diabetes and other factors for MetS. A structured adjustment scheme was used to adjust for confounding effects of other variables. First, we performed univariable analysis. Second, we performed multivariable analysis with stepwise selection of confounders from traditional and potential MetS risk factors (*P* = 0.05 for entry and *P* = 0.10 for exit), including age, gender, region, education attainment, family history of diabetes, smoking and alcohol consumption habits. Third, we further adjusted for HOMA2-IR to check whether the increased or decreased risks of MetS in T2DM and T1DM was attributable to different levels of insulin resistance in those types of diabetes. A two-sided *P* \< 0.05 was considered statistically significant.

Results {#s3}
=======

Characteristics of the Study Patients
-------------------------------------

The cohort had 52.6 (SD: 11.5) years of mean age, and 0.2 (SD: 0.3) years of duration of diabetes. Males accounted for 59.8% and females accounted for 40.2% of the patients. The overall prevalence of MetS was 66.5% (95% CI: 65.8--67.2%). Participants with MetS were older, more insulin-resistant, and had a larger proportion of males and a smaller proportion of GADA-positive subjects than those without MetS ([Table 1](#T1){ref-type="table"}).

###### 

Demographic and clinical characteristics of the study patients stratified by metabolic syndrome.

                                             **Metabolic syndrome**   **Non-metabolic syndrome**   ***P*-value[^\*^](#TN1){ref-type="table-fn"}**   **Effect size**
  ------------------------------------------ ------------------------ ---------------------------- ------------------------------------------------ -----------------
  *n*                                        10,304                   5,188                                                                         
  Age (year)                                 52.8 ± 11.6              52.2 ± 11.2                  0.001                                            0.05
  Male, *n (%)*                              6,384/10,304 (62.0)      2,877/5,188 (55.5)           \<0.0001                                         0.06
  South, *n (%)*                             6,824/10,304 (66.2)      3,683/5,188 (71.0)           \<0.0001                                         0.05
  Educational level                                                                                                                                 
      Tertiary or above, *n (%)*             1,966/9,475 (20.7)       916/4,870 (18.8)             0.006                                            0.02
      Senior high school, *n (%)*            2,412/9,475 (25.5)       1,313/4,870 (27.0)           0.052                                            0.02
      Junior high school or lower, *n (%)*   5,097/9,475 (53.8)       2,641/4,870 (54.2)           0.620                                            0.00
  Current smoking, *n (%)*                   3,361/10,189 (33.0)      1,390/5,126 (27.1)           \<0.0001                                         0.06
  Current alcohol consumption, *n (%)*       2,067/10,136 (20.4)      739/5,103 (14.5)             \<0.0001                                         0.07
  BMI (kg/m^2^)                              25.73 ± 3.38             22.67 ± 2.99                 \<0.0001                                         0.95
  Waist circumference (cm)                   91.78 ± 9.67             81.30 ± 8.44                 \<0.0001                                         1.15
  Systolic BP (mmHg)                         131.8 ± 16.2             120.7 ± 14.3                 \<0.0001                                         0.73
  Diastolic BP (mmHg)                        82.4 ± 10.6              75.9 ± 8.9                   \<0.0001                                         0.66
  TGs (mmol/L) ł                             2.14 (1.55--3.19)        1.17 (0.88--1.51)            \<0.001                                          0.51
  LDL-C (mmol/L)                             2.88 ± 1.00              2.85 ± 0.96                  0.097                                            0.03
  HDL-C (mmol/L)                             1.09 ± 0.34              1.36 ± 0.37                  \<0.0001                                         0.76
  HbA1c (%) ł                                9.0 (7.2--11.2)          8.9 (6.8--11.6)              0.823                                            0.01
  HOMA2-B (%) ł                              46.1 (25.8--73.2)        37.7 (19.4--62.6)            \<0.001                                          0.12
  HOMA2-IR ł                                 1.70 (1.12--2.38)        1.15 (0.71--1.68)            \<0.001                                          0.28
  DKA, *n (%)*                               578/10,153 (5.7)         371/5,136 (7.2)              0.0002                                           0.03
  GADA positivity, *n (%)*                   321/10,304 (3.1)         464/5,188 (8.9)              \<0.0001                                         0.13
  Family history of diabetes, *n (%)*        2,832/10,119 (28.0)      1,442/5,115 (28.2)           0.791                                            0.00
  Use of insulin treatment, *n (%)*          2,255/10,277 (21.9)      1,392/5,166 (26.9)           \<0.0001                                         0.06
  Use of antihypertensive agents, *n (%)*    3,058/10,277 (29.8)      452/5,166 (8.7)              \<0.0001                                         0.24
  Use of lipid-lowering agents, *n (%)*      1,336/10,277 (13.0)      388/5,166 (7.5)              \<0.0001                                         0.08
  Types of diabetes                                                                                                                                 
      Type 1, *n (%)*                        108 (1.0)                208 (4.0)                    \<0.0001                                         0.10
      Type 2, *n (%)*                        9,936 (96.4)             4,653 (89.7)                 \<0.0001                                         0.14
      LADA, *n (%)*                          260 (2.5)                327 (6.3)                    \<0.0001                                         0.09

*BP, blood pressure; DKA, diabetic ketoacidosis; data were presented as number (%) for categorial variables, and mean ± SD or median (interquartile range) for continuous variables*.

*P-value: for continuous variables, estimates were based on Student t-test for normally-distributed data, or Mann-Whitney U test for highly-skewed data with the mark (ł); for categorical variables, estimates were based on χ^2^ test or Fisher\'s exact test. For a Student t-test the Effect Size (Cohen\'s d) Calculator has been chosen. For the Mann-Whitney test an effect size can be achieved by dividing the Z-value with the square root of total number. For categorical data, the effect size is calculated by dividing chi-square value with the total number, and then take the square root*.

Types of Diabetes and OR of MetS
--------------------------------

The prevalence of MetS was 34.2% in T1DM, 44.3% in LADA and 68.1% in T2DM (*P* \< 0.05 for comparison of any pairs of them). Using LADA as the referent group, patients with T2DM had higher odds of MetS (OR: 2.69, 95% CI: 2.27--3.17), while patients with T1DM had lower odds of MetS (OR: 0.65, 95% CI: 0.49--0.87) (Model 1, [Table 2](#T2){ref-type="table"}). The decreased risk of MetS in T1DM (OR: 0.68, 95% CI: 0.50--0.92) and increased risk of MetS in T2DM (OR: 2.82, 95% CI: 2.36--3.37) persisted after adjustment for age, gender, region, education attainment, family history of diabetes, smoking and alcohol consumption habits (Model 2, [Table 2](#T2){ref-type="table"}). After further adjustment for HOMA2-IR, T2DM remained to be associated with significantly increased risk of MetS (OR: 2.13, 95% CI: 1.76--2.57). On the other hand, the decreased risk of MetS in T1DM was no longer significant (OR: 0.96, 95% CI: 0.70--1.33) (Model 3, [Table 2](#T2){ref-type="table"}).

###### 

Odds ratio of clinical factors for MetS vs. non-MetS in Chinese newly diagnosed diabetes.

                                    **Model 1[^\*^](#TN2){ref-type="table-fn"}**   **Model 2[^\*^](#TN2){ref-type="table-fn"}**   **Model 3[^\*^](#TN2){ref-type="table-fn"}**                                  
  --------------------------------- ---------------------------------------------- ---------------------------------------------- ---------------------------------------------- ---------- ------------------- ----------
  Types of diabetes                                                                \<0.0001                                                                                      \<0.0001                       \<0.0001
      Type 2                        2.69 (2.27--3.17)                              \<0.0001                                       2.82 (2.36--3.37)                              \<0.0001   2.13 (1.76--2.57)   \<0.0001
      Type 1                        0.65 (0.49--0.87)                              0.003                                          0.68 (0.50--0.92)                              0.012      0.96 (0.70--1.33)   0.815
      LADA                          Reference                                                                                     Reference                                                 Reference           
  Age, year                         1.01 (1.00--1.01)                              0.001                                          1.01 (1.00--1.01)                              0.002      1.01 (1.00--1.01)   0.012
  Male vs. female                   1.31 (1.22--1.40)                              \<0.0001                                       1.19 (1.09--1.29)                              0.0001     1.29 (1.18--1.40)   \<0.0001
  South vs. North                   0.80 (0.75--0.86)                              \<0.0001                                       0.81 (0.75--0.88)                              \<0.0001   0.90 (0.83--0.98)   0.019
  Educational level                                                                0.011                                                                                         0.013                          0.005
      Tertiary or above             1.11 (1.02--1.22)                              0.023                                          1.02 (0.93--1.13)                              0.667      0.97 (0.87--1.08)   0.542
      Senior high school            0.95 (0.88--1.03)                              0.238                                          0.89 (0.82--0.97)                              0.009      0.86 (0.78--0.94)   0.001
      Junior high school or lower   Reference                                                                                     Reference                                                 Reference           
  Family history of diabetes        0.99 (0.92--1.07)                              0.791                                          --                                                        --                  
  Current smoking                   1.32 (1.23--1.43)                              \<0.0001                                       1.12 (1.01--1.23)                              0.025      --                  
  Current alcohol consumption       1.51 (1.38--1.66)                              \<0.0001                                       1.34 (1.209--1.49)                             \<0.0001   1.36 (1.22--1.52)   \<0.0001
  HOMA2-IR                                                                         \<0.0001                                       NA                                                                            \<0.0001
      Upper quartile                5.04 (4.52--5.61)                              \<0.0001                                       NA                                                        4.68 (4.16--5.25)   \<0.0001
      Mid-high quartile             2.85 (2.58--3.14)                              \<0.0001                                       NA                                                        2.67 (2.40--2.97)   \<0.0001
      Mid-low quartile              1.54 (1.41--1.69)                              \<0.0001                                       NA                                                        1.40 (1.32--1.61)   \<0.0001
      Bottom quartile               Reference                                                                                     NA                                                        Reference           

*CI, confidence interval; OR, odds ratio; NA, not applicable*.

*Model 1 was from univariable analysis. Model 2 was adjusted for age, gender, region, education attainment, family history of diabetes, smoking, and alcohol consumption as selected by forward stepwise (P = 0.05 for entry and P = 0.10 for exclusion). Model 3 was further adjusted for HOMA2-IR*.

Other Determinants of MetS in Newly Diagnosed Diabetes
------------------------------------------------------

In addition to types of diabetes, MetS was also independently associated with older age (OR: 1.01, 95% CI: 1.00--1.01), male gender (OR: 1.29, 95% CI: 1.18--1.40) and alcohol consumption (OR: 1.36, 95% CI: 1.22--1.52). Also, the OR of the bottom vs. top quartiles of HOMA2-IR for MetS was statistically significant (OR: 4.68, 95% CI: 4.16--5.25). Residence in the South (OR: 0.90, 95% CI: 0.83--0.98) and senior high school education attainment (OR: 0.86, 95% CI: 0.78--0.94) were associated with lower risks of MetS (Model 3, [Table 2](#T2){ref-type="table"}).

Composition of MetS by Types of Diabetes
----------------------------------------

For different types of diabetes, the most frequent combinations were hypertension + elevated waist circumference in T2DM, hypertension + elevated waist circumference + hypertriglyceridemia in LADA, and hypertriglyceridemia + low HDL-C in T1DM. With respect to the frequencies of individual features of the MetS, hypertension was the most common abnormality regardless of types of diabetes, while an elevated waist circumference was least frequently seen in T1DM ([Table 3](#T3){ref-type="table"}).

###### 

Number and percentage of patients with metabolic abnormalities by type of diabetes.

                                                                                                     **T1DM**            **LADA**            **T2DM**
  -------------------------------------------------------------------------------------------------- ------------------- ------------------- -------------------
  *n*                                                                                                316                 587                 14,589
  Waist circumference ≥90 cm in male and 85 cm in female, *n (%)*[^\*^](#TN3){ref-type="table-fn"}   71 (22.5)           186 (31.7)          7,332 (50.3)
  Systolic/Diastolic BP ≥130/85 mmHg, *n (%)*[^\*^](#TN3){ref-type="table-fn"}                       111 (35.1)          281 (47.9)          8,741 (59.9)
  TGs ≥1.7 mmol/L, *n (%)*[^\*^](#TN3){ref-type="table-fn"}                                          88 (27.8)           199 (33.9)          7,516 (51.5)
  HDL-C \<1.04 mmol/L, *n (%)*[^\*^](#TN3){ref-type="table-fn"}                                      106 (33.5)          172 (29.3)          5,569 (38.2)
  Metabolic syndrome, *n (%)*[^\*^](#TN3){ref-type="table-fn"}                                       108 (34.2)          260 (44.3)          9,936 (68.1)
  HOMA2-IR                                                                                           0.25 (0.09--0.52)   1.01 (0.53--1.67)   1.53 (1.00--2.20)

*T1DM, type 1 diabetes mellitus; LADA, latent autoimmune diabetes in adults; T2DM, type 2 diabetes mellitus; BP, blood pressure*.

*Data of patients with parameters above the cut-point defined by CDS metabolic syndrome criteria were expressed as number (%); HOMA2-IR were expressed as median (interquartile range)*.

Discussion {#s4}
==========

Our study generated novel findings that MetS was highly prevalent in newly diagnosed diabetes in China, with approximately two-thirds in T2DM and more than one-third in autoimmune diabetes. Patients with T2DM had the highest risk of MetS, and the increased risk could not be entirely attributable to the severity of insulin resistance and other risk factors. On the other hand, patients with LADA also had a higher risk of MetS than those with T1DM, but the increased risk in LADA was attributable to increased insulin resistance.

Several small studies had reported the prevalence of MetS in T2DM, LADA and T1DM in different populations, predominantly in Caucasians and Hispanics ([@B9], [@B23]). In a Spain study (*n* = 640), the prevalence of MetS was 67.2% in T2DM, 37.3% in LADA and 15.5% in T1DM ([@B23]). Asians have a higher body fat percentage and are more prone to central obesity and insulin resistance than their western counterparts at a given age, sex, and BMI ([@B24]). Furthermore, inadequacy of compensatory insulin secretion, which could not increase in proportion with the severity of insulin resistance, is prominent in Asian diabetic population ([@B24]). Asian population differed from Caucasians also in genetics, diet and lifestyles ([@B24], [@B25]), limiting the extrapolation of the aforementioned findings to Asians. However, there is still a lack of relevant studies conducted throughout the entire diabetes spectrum in Chinese population with large sample size and geographical diversity. In a small sample of patients with newly diagnosed diabetes (*n* = 588), our group found that the prevalence of the National Cholesterol Education Program-Adult Treatment Panel III (NCEP-ATP III) criteria-defined MetS was 10.8% in T1DM, 62.4% in LADA and 69.5% in T2DM ([@B26]). In this large nation-wide multicenter survey, we updated the prevalence of MetS to be 34.2% in T1DM, 44.3% in LADA and 68.1% in T2DM. The prevalence of MetS in our survey was similar to that reported in the Action LADA study in Europe ([@B9]). Differently, the prevalence of MetS in T1DM in our survey was much higher than the 10.1% in T1DM reported in a previous Chinese survey (*n* = 849) ([@B27]). Given that the prevalence of MetS increases with increasing age ([@B28]), and the much younger age of T1DM patients in that Chinese survey (the median age: 22 years) ([@B27]), the observed high prevalence of MetS in our patients is not at odds with the findings of that Chinese survey. Using age at diagnosis ≥30 years as one of the inclusion criteria and the CDS criteria for definition of MetS, which was more appropriate for Chinese population for cardiovascular risk assessment ([@B18]), our survey generated a more reliable estimation of the prevalence of MetS in newly diagnosed diabetes. Had we adopted the NCEP-ATP III criteria for diagnosis of MetS, the prevalence of MetS was 38.6% in T1DM, 50.6% in LADA, 74.1% in T2DM.

In addition to types of diabetes, our survey also found that older age, male gender, residence in the South, senior high school education attainment, alcohol consumption, and higher HOMA2-IR were all associated with MetS in newly diagnosed diabetes. Previous studies found that older age ([@B28]) and higher HOMA-IR ([@B7]) were associated with higher risks of MetS in diabetes, while residence in the South ([@B29]) and a relatively high education level ([@B15]) were associated with lower risks of MetS, in support of our findings. However, we did not find an association between smoking and MetS, inconsistent with other studies conducted in the general population ([@B30]). Also, our findings that alcohol consumption and male gender were associated with increased odds ratio of MetS, were in contrast to the literature ([@B29], [@B31]). In this regard, moderate alcohol consumption proved to be cardiovascular-protective ([@B32]). Because our definition of alcohol drinkers was more likely to include heavy drinkers and misclassify mild-to-moderate drinkers to non-drinkers, our findings regarding the association between alcohol consumption and MetS risk were more likely driven by heavy drinking. Types of alcoholic beverages were not documented in our study and further studies are needed to address or confirm types, frequency and quantity of alcohol consumption in their relationships with increased risk of MetS. Regarding the gender-specific difference in the risk for MetS, there was still no unequivocal conclusion, and numerous studies reported that MetS risk in women was not inferior to that in men ([@B9], [@B29]). Indeed, females are genetically more insulin resistant than males ([@B33]). However, a complex interplay of sex hormones, metabolic cytokines, environmental factors and lifestyles on cardiovascular profiles might confound the observed risk ([@B34], [@B35]). Moreover, the presence of overt diabetes might considerably attenuate the female-male gradient ([@B36]). The use of different criteria for MetS further contributed to the inconsistency among studies.

MetS is a strong risk factor for T2DM and the increased prevalence of MetS may be one of the causes for rapid secular increase in the prevalence of T2DM in China ([@B37]). It can be expected that there was a high prevalence of MetS in patients with T2DM. It is of interest to observe that the prevalence of MetS was also quite high in LADA and T1DM in our and other populations. In this regard, the Action LADA study reported that the increased risk of MetS in autoimmune diabetes, i.e., T1DM and LADA, as compared to non-diabetic controls, was attributable to hyperglycemia, but the increased risk of MetS in T2DM was not. The authors of the study suggested that autoimmune diabetes was not due to decreased insulin sensitivity ([@B9]). It is established that insulin resistance in LADA, albeit less severe than in T2DM, was more pronounced than in T1DM ([@B38]). Similar to T2DM, studies also showed that sweetened beverage intake, overweight/obesity and physical inactivity were strongly predictive of LADA ([@B39], [@B40]). In this connection, our study found that LADA had a higher risk of MetS than T1DM and the increased MetS risk in LADA was due to increased insulin resistance. Because MetS greatly increases the risk of cardiovascular disease in both the general population ([@B1]) and the diabetic population ([@B41]--[@B43]), our findings support use of insulin sensitizers in LADA. Our study also confirms that T2DM was associated with markedly higher risk of MetS, independent of traditional risk factors and even insulin resistance, supporting multicausality of cardiovascular disease in T2DM. Indeed, apart from decreased insulin sensitivity, many other abnormalities such as endothelial stress, chronic low-grade systemic inflammation and hypercoagulation were common in both T2DM and MetS, and these abnormalities intertwined to form a complex network of causality for macro- and micro-vascular diseases in T2DM ([@B44]).

Our study has clinical and public health implications. A focus on individual components of MetS, namely hyperglycemia, hypertension, obesity and dyslipidemia separately, is routine in clinical practice, while MetS as an entity is unaddressed given the lack of evidence at population level, especially in Chinese, and our study filled the gap. The findings indicate that newly-diagnosed diabetic population in China are facing an epidemic of MetS, and thus, clinicians should pay more attention to the cardiometabolic profiles of diabetic patients and develop targeted strategies against the risk factors of MetS. Furthermore, although our previous pilot study showed rosiglitazone might have a beneficial effect on beta cell function of LADA patients ([@B45]), the roles of insulin sensitizers on the long-term cardiovascular outcomes are largely unknown. Our results suggest that insulin resistance accounted for the residual MetS risk in LADA patients. Future prospective cohort studies are warranted to confirm whether MetS and MetS components are associated with increased risks of diabetes complications, and randomized controlled trials may also be needed if the findings were confirmed by prospective cohorts, to test the efficacy and effectiveness of insulin sensitizers in the management of LADA for potential cardiovascular benefits.

Our study had several strengths. First, our study was a large multi-center study with subjects recruited from tertiary care hospitals across the seven geographic regions of China. Thus, this study had a good representativeness of patients with newly diagnosed adult-onset diabetes in China. Second, the antibody assay was performed in a single well-equipped laboratory, which ensured high quality measurement of the antibody and etiologic classification of diabetes. Our study also had limitations. First, we only used GADA titers to define LADA and some of the "true LADA" patients may be misclassified as T2DM patients. However, negative GADA only represented \<5% of the total LADA patients ([@B46]), so major bias due to misclassification of LADA was unlikely. Second, socio-economic status was not collected in our survey. Third, the participating hospitals used different C-peptide assay kits although the same method was used. This may have led to a large variance in C-peptide concentrations. However, the participating hospitals were all tertiary care center with good quality control measures in operation. Potential bias due to the non-standardization should be small if any. Finally, our study was a cross-sectional survey and the associations reported by us were not necessarily suggesting causal relationships. Longitudinal studies are needed to examine whether and how the prevalence of MetS by types of diabetes changes over time.

Conclusions {#s5}
===========

In summary, our study found that MetS was highly prevalent, up to 66.5% in newly-diagnosed diabetes, with the risks being the highest in T2DM and the second highest in LADA. The increased risk of MetS in T2DM could not be explained by traditional risk factors of MetS and increased insulin resistance. However, the higher risk of MetS in LADA vs. T1DM was attributable to increased insulin resistance in LADA. These findings support use of insulin sensitizers in LADA for management of CVD risk factors. Besides, age, gender, geographical residence, education attainment, alcohol consumption and HOMA2-IR were independent determinants of MetS. Further prospective cohort studies are needed to test whether targeted strategies against these risk factors could lower the Mets rates in diabetes.
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